PAM
TARA icon

PVG Asset Management’s Protara Therapeutics TARA Stock Holding History

PVG Asset Management’s Portfolio TARA Stock Details TARA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-250
Closed -$2.6K – 91
2019
Q3 		$2.6K Buy
+250
New +$3.58K ﹤0.01% 78

Other funds holding TARA

A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PVG Asset Management's TARA Position: Q4 2019 in Review

PVG Asset Management sold out of Protara Therapeutics (TARA) in Q4 2019, closing a stake of 250 shares — an estimated $2.6K sold.

PVG Asset Management first reported a position in TARA in Q3 2019 and held it in 1 quarter. The position peaked at $2.6K in Q3 2019. 16 funds tracked by Wall St. Rank hold TARA as of Q4 2019.

  • PVG Asset Management reported no remaining Protara Therapeutics position as of Q4 2019 after selling out during the quarter.
  • PVG Asset Management sold 250 Protara Therapeutics shares in Q4 2019, an estimated $2.6K.
  • PVG Asset Management first reported a position in Protara Therapeutics in Q3 2019 and held it in 1 quarter.
  • PVG Asset Management's Protara Therapeutics position peaked at $2.6K in Q3 2019.
  • 16 funds tracked by Wall St. Rank held Protara Therapeutics as of Q4 2019.

Based on PVG Asset Management's 13F filing for Q4 2019, filed 26 Feb 2020.